SK Biopharm, KR7326030004

SK Biopharm stock: Growth plan extends beyond cenobamate

Published on 11/20/2026 at 02:23 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
SK Biopharm stock is broadening its pipeline around cenobamate and Opicalmib. Management also outlined oncology, artificial intelligence and open innovation plans.

Growth plans broaden beyond cenobamate

  • SK Biopharm is pursuing additional indications and formulations for its epilepsy treatment.
  • Opicalmib and oncology technologies are intended to broaden the central nervous system pipeline.
  • Management also presented artificial intelligence and open innovation as strategic growth tools.
SK Biopharm, KR7326030004, Illustration mit AI erstellt.

SK Biopharm presented a medium- to long-term growth strategy at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026. The plan combines further expansion of cenobamate, the epilepsy treatment marketed as Xcopri in the United States, with new central nervous system assets and oncology research. The Herald Business reported that cenobamate had surpassed 300,000 cumulative patients worldwide as of September.

Cenobamate remains the core growth engine

SK Biopharm is seeking broader use of cenobamate beyond its current adult partial-onset seizure indication. The company is targeting primary generalized tonic-clonic seizures in patients aged 12 and older, pediatric partial-onset seizures and new formulations such as an oral suspension.

The treatment has expanded across Northeast Asia after launches in China, South Korea and Japan. The company also cited further commercial expansion in Latin America, including Peru, Chile and Brazil.

Pipeline diversification moves forward

Opicalmib, also known as BHV-7000, was in-licensed from Biohaven in August as a follow-on epilepsy product for SK Biopharm's US direct-sales platform. Patient enrollment in the RISE3 Phase 2/3 trial for adults with partial-onset seizures has been completed.

Beyond epilepsy, SK Biopharm is developing next-generation oncology approaches, including radioligand therapy and targeted protein degradation. Chief Executive Lee Dong-hoon also presented an AI-Native Operation strategy for drug discovery and corporate efficiency, alongside an East-West Bridge model for connecting Asian biotech assets with global markets.

Company profile and market context

SK Biopharmaceuticals is a South Korean biotechnology company focused on researching, developing and commercializing therapies for central nervous system disorders. Its portfolio includes cenobamate for epilepsy and solriamfetol for excessive daytime sleepiness associated with narcolepsy or obstructive sleep apnea. The company is headquartered in Seongnam and is a subsidiary of SK Inc.

SK Biopharm at a glance

  • Company: SK Biopharmaceuticals Co., Ltd.
  • ISIN: KR7326030004
  • Ticker: 326030.KS
  • Headquarters: Seongnam, South Korea
  • Sector: Healthcare
  • Industry: Biotechnology
  • Chief executive: Dong Hoon Lee

South Korean biotechnology shares trade within the broader market environment tracked by the KOSPI.

More news and analyses on SK Biopharm stock.

Disclaimer...
en | KR7326030004 | SK BIOPHARM | boerse | 70538279 | bgmi